Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
St Bartholomew's Hospital · Queen Mary University of London · +20 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,410
total citations
- FWCI
- 143.36
- Percentile
- 100%
- References
- 29
Citations per year
Authors
24- TPThomas PowlesCorresponding
St Bartholomew's Hospital, Queen Mary University of London
- IDIgnacio Durán
Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Hospital Universitario Virgen del Rocío
- MSMichiel S. van der Heijden
The Netherlands Cancer Institute
- YLYohann Loriot
Université Paris-Saclay, Institut Gustave Roussy
- NJNicholas J. Vogelzang
Comprehensive Cancer Centers of Nevada
Topics & keywords
Topics
Keywords
- Metastatic Urothelial Carcinoma
- Atezolizumab
- Medicine
- Oncology
- Internal medicine
- Clinical endpoint
- Docetaxel
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.